pharma · Hereditary Angioedema · Diabetic Macular Edema · KALV
Kalvista Pharmaceuticals (Ireland)
Kalvista Pharmaceuticals (Ireland) Limited
Kalvista Pharmaceuticals (Ireland) is a pharma organization headquartered in Framingham, USA. It trades on NYSE under ticker KALV. Primary therapeutic focus areas include Hereditary Angioedema, Diabetic Macular Edema, An
Framingham, USA HQ
279 Employees
Public company Type
KALV · NYSE Ticker
Company details
- Status
- Public
- HQ
- Framingham, USA
- Employees
- 279
- Programs
- 8
- Drugs
- 6
- Patents
- 24
KVD900 600 mg
Phase 3 · small molecule · Hereditary Angioedema
KVD900 600 mg for Hereditary Angioedema is a Phase 3 program (small_molecule) at Kalvista Pharmaceuticals (Ireland) Limited with 2 ClinicalTrials.gov record(s).
Internal code KVD900-302a
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Kalvista Pharmaceuticals (Ireland) Limited
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Hereditary Angioedema
- Status
- active
- Trials
- 2